<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374476</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-1827</org_study_id>
    <nct_id>NCT02374476</nct_id>
  </id_info>
  <brief_title>Bipolar Ventricular Tachycardia (VT) Study</brief_title>
  <official_title>Bipolar Catheter Ablation for the Treatment of Refractory Scar-Related Ventricular Arrhythmia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Srinivas Dukkipati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-randomized study will examine the safety and efficacy of irrigated bipolar&#xD;
      radiofrequency (RF) ablation in the treatment of ventricular tachycardia (VT) in patients for&#xD;
      whom standard VT unipolar RF ablation has been unsuccessful. VT is a serious abnormality of&#xD;
      the heart's electrical system. Ablation is a procedure that cauterizes heart tissue using&#xD;
      catheters (long tubes that can be moved within or along the outside of the heart).&#xD;
      Cauterizing the heart tissue is accomplished by using heat to damage the abnormal heart&#xD;
      tissue that is not working well so that it can stop affecting the rest of the heart. Usually,&#xD;
      heat is delivered using a unipolar catheter, in which energy travels from the catheter tip to&#xD;
      a grounding pad. This research study seeks to find out if a bipolar ablation catheter, in&#xD;
      which the energy travels between two catheter tips on either side of the heart muscle, can be&#xD;
      used to eliminate the arrhythmia when the unipolar ablation is unsuccessful. The hypothesis&#xD;
      is that the increased current density and improved rates of transmural lesion creation seen&#xD;
      with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no&#xD;
      increased risk of complication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVE This study will examine the role of irrigated bipolar radiofrequency (RF)&#xD;
      ablation for the treatment of intramural ventricular tachycardia in patients who have failed&#xD;
      standard unipolar RF ablation. The hypothesis is that the increased current density and&#xD;
      improved rates of transmural lesion creation seen with bipolar RF ablation will lead to&#xD;
      successful arrhythmia termination with minimal or no increased risk of complication.&#xD;
&#xD;
      INTRODUCTION, RATIONALE Radiofrequency (RF) ablation is the most commonly employed method for&#xD;
      the catheter treatment of cardiac arrhythmias. Myocardial scar serves as the most frequent&#xD;
      substrate for the genesis of both atrial and ventricular arrhythmia. Such scar frequently&#xD;
      contains surviving myocyte bundles interspersed with fibrotic tissue, which leads to slow&#xD;
      conduction. Areas of denser fibrosis cause conduction block. When appropriately arranged,&#xD;
      conduction through or around these scars leads to the creation of a &quot;reentry&quot; circuit through&#xD;
      which an arrhythmia is generated and maintained. Each reentry circuit contains within it an&#xD;
      area called the isthmus, a portion of the circuit located in a position intimately related to&#xD;
      the scar border zone. Electrical activation travels slowly through the isthmus before&#xD;
      breaking out into normal myocardium. Ablation at the site of an isthmus will terminate a&#xD;
      reentrant tachycardia.&#xD;
&#xD;
      A variety of techniques, including electroanatomic mapping and activation, entrainment, and&#xD;
      substrate mapping, are employed during electrophysiologic (EP) study to identify areas of&#xD;
      myocardial scar and potential isthmus sites. Points or lines of ablation using RF energy are&#xD;
      then created in an attempt to interrupt the reentry circuit. Typically, unipolar RF energy is&#xD;
      applied via a catheter tip electrode to the endocardial or epicardial surface of the heart&#xD;
      and grounded via an electrode pad placed on the patient's skin. RF energy in this setting is&#xD;
      dispersed through the entirety of the tissue between catheter tip and grounding pad. The&#xD;
      standard 7-French, 4-mm tip catheters are highly successful at ablating circuits located&#xD;
      within a few millimeters of the catheter tip. A focal, 1mm area of resistive heating occurs&#xD;
      within the myocardium immediately in contact with the catheter tip; myocardial cell death&#xD;
      occurs several millimeters more deeply through passive, conductive heating, which spreads&#xD;
      outward from the contact point.&#xD;
&#xD;
      While the standard catheter is effective at the ablation of superficial arrhythmias, it has&#xD;
      proven more problematic when used for deep myocardial sites or for creating transmural&#xD;
      lesions. A number of alternatives have been developed in an attempt to access these sites.&#xD;
      8-mm or 10-mm catheter tips are able to create larger zones of resistive heating, delivering&#xD;
      direct RF energy to a larger area of myocardium. A larger interface between catheter tip and&#xD;
      blood improves cooling and allows for the delivery of more power without a rise in impedence.&#xD;
      The clinical use of these larger catheters can, however, be limited by rapid temperature&#xD;
      rises at the catheter-tissue interface, resulting in thrombus formation, char, and &quot;steam&#xD;
      pop&quot; rupture of the endocardial surface. The use of irrigated ablation catheters have&#xD;
      improved upon the ability to deliver RF energy without a sustained rise in impedance. Both&#xD;
      open irrigated- and closed-loop irrigated catheters circulate saline along the catheter&#xD;
      tip-myocardial interface, allowing for continued delivery of RF current without thrombus&#xD;
      formation at the endocardial surface. Intramyocardial temperature rises accordingly without a&#xD;
      concomitant endocardial temperature surge, creating larger and deeper myocardial ablation&#xD;
      zones. Catheters featuring a retractable needle tipped electrode with intramyocardial saline&#xD;
      infusion have also shown promise as a means of accessing deep myocardial circuits in&#xD;
      ventricular tachycardia ablation, but are not currently available in the US. Transcoronary&#xD;
      ethanol ablation has also been employed with moderate success in patients with arrhythmias&#xD;
      resistant to endocardial catheter ablation. This technology, however, grants only limited&#xD;
      control over the size of the resulting infarct and is restricted by the need for perfusion of&#xD;
      the scar zone by an accessible coronary artery.&#xD;
&#xD;
      Nevertheless, there remain occasions in which an arrhythmia cannot be eliminated by standard&#xD;
      unipolar ablation technique. This is seen most frequently due to deep intramural ventricular&#xD;
      tachycardia, sometimes encountered following myocardial infarction. Both standard and&#xD;
      alternative ablation strategies are frequently either unavailable or inadequate for&#xD;
      termination of these arrhythmias.&#xD;
&#xD;
      Recently, several centers have employed irrigated bipolar ablation (BA) to target arrhythmias&#xD;
      not amenable to unipolar ablation. During BA, two catheters are connected to either pole of&#xD;
      an RF generator, allowing either catheter to function as the &quot;active&quot; catheter and the other&#xD;
      the &quot;return&quot; catheter. Rather than being dispersed between the catheter tip and a distant&#xD;
      grounding pad, BA concentrates energy between two catheter tips positioned on opposing sides&#xD;
      of a target scar. BA may thus improve lesion transmurality through synergistic, simultaneous&#xD;
      heating and increased current density leading to concentrated thermal injury.&#xD;
&#xD;
      Initial experience in the use of BA technology in mammalian hearts demonstrated that it could&#xD;
      successfully be applied to create discrete areas of myocardial necrosis with minimal risk of&#xD;
      complication. When compared to unipolar ablation, several studies suggested that BA could&#xD;
      create larger areas of necrosis and transmural lesions with only rare episodes of&#xD;
      perforation. Subsequent experience in human hearts was predominantly surgical: a large number&#xD;
      of observational studies and reviews demonstrated the effectiveness and safety of BA in&#xD;
      patients undergoing pulmonary vein isolation and Cox-Maze surgery as either isolated&#xD;
      procedures or as adjuncts to valve replacement or coronary artery bypass surgery.&#xD;
&#xD;
      Despite its broad use during surgical ablation, the application of BA during catheter-based&#xD;
      therapies is limited. Recently, our group demonstrated the utility of BA in both an in vitro&#xD;
      model and in a series of patients with arrhythmia resistant to unipolar ablation. When&#xD;
      compared to unipolar RF ablation, BA was found to be more likely to achieve transmural&#xD;
      lesions in a porcine heart model (33% vs 82%, respectively, p = 0.001) and could do so in&#xD;
      tissue up to 25 mm thickness. Clinically, all septal atrial flutters, 5 of 6 septal VTs, and&#xD;
      2 of 4 free-wall VTs were successfully acutely terminated.&#xD;
&#xD;
      The proposed study will further examine the role of BA in patients with ventricular&#xD;
      tachycardia resistant to standard ablation techniques.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2015</start_date>
  <completion_date type="Actual">September 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from recurrent VT</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from recurrent VT at 6 months, defined as sustained ventricular tachycardia lasting longer than 30 seconds and identified due to clinical symptoms or during device interrogation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural complications</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of procedural complications which includes death, stroke, MI, heart failure, conduction abnormalities, pericardial effusion requiring drainage, hematoma, pseudoaneurysm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-ablation inducibility</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of the induction of any sustained arrhythmia post-ablation, with a duration &gt; 15 seconds of MMVT. Post ablation inducibility is measured via program stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to termination</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of bipolar ablation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Bipolar Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bipolar Ablation</intervention_name>
    <description>Patients will undergo bipolar ablation if unipolar ablation unsuccessful</description>
    <arm_group_label>Bipolar Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  â‰¥ 18 years of age.&#xD;
&#xD;
          -  The study will include all forms of scar VT--both ischemic (post-myocardial&#xD;
             infarction) and non-ischemic (eg sarcoid, amyloid, dilated)--as determined by cardiac&#xD;
             MRI and/or voltage mapping at the time of VT ablation.&#xD;
&#xD;
          -  Intramural VT not terminable with unipolar ablation once enrolled in the Bipolar study&#xD;
             or previous failed unipolar ablation within 6 months prior to enrollment.&#xD;
&#xD;
          -  Ability to understand the requirements of the study and sign the informed consent&#xD;
             form.&#xD;
&#xD;
          -  Willingness to adhere to study restrictions and comply with all post- procedural&#xD;
             follow-up requirements&#xD;
&#xD;
          -  Projected lifespan greater than 1 year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tissue Thickness less than 5 mm as assessed by electroanatomic mapping, CT, or MRI.&#xD;
&#xD;
          -  MI or CABG within 6 weeks.&#xD;
&#xD;
          -  NYHA Class IV CHF.&#xD;
&#xD;
          -  Women known to be pregnant or to have positive beta-HCG.&#xD;
&#xD;
          -  Participation in another study that would interfere with this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Dukkipati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Womans Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Czechia</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Srinivas Dukkipati</investigator_full_name>
    <investigator_title>Co-Director EP Service</investigator_title>
  </responsible_party>
  <keyword>VT</keyword>
  <keyword>Refractory VT</keyword>
  <keyword>VT Storm</keyword>
  <keyword>Ventricular Fibrillation</keyword>
  <keyword>V Fib</keyword>
  <keyword>VF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

